the absence of ERK phosphorylation might explain the lack of clinical effectiveness of imatinib in these tumors—which was unexpected owing to the high levels of the imatinib target KIT.

Imatinib (IMKELDI) is the first oral liquid TKI approved for GIST, MDS, MPD, CML, and Ph+ ALL, enhancing treatment accessibility. The oral solution offers precise dosing, benefiting patients with ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...